Sponsored
Krystal Haynes, Senior Director of Business Development, ICS, at Cencora, outlines the challenges facing cell and gene therapy manufacturers as they attempt to move products from clinical development to commercial availability.
Krystal Haynes, Senior Director - Business Development, ICS
Advertisement
Articles by Krystal Haynes, Senior Director - Business Development, ICS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Payers Want Real-World Evidence. Why Aren't They Using It?
2
Philip Sclafani: Will PBM Reform Actually Lower Net Drug Costs?
3
How the US Section 301 Probe Targets Germany's Drug Pricing
4
Why UPS Committed $48M to Cold-Chain Cross-Dock Buildout
5